INDIA MARKET LENS

Biocon Limited (BIOCON): research summary

Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Biocon Limited, explained in plain English.

  • Biocon Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
  • BIOCON closed at ₹364.40 on 20 November 2026.
  • Over the past year the shares are down 8.2%, trading between ₹318.40 and ₹447.15.
  • Reported fundamentals show return on equity of 0.97%, a net margin of 2.6%, debt to equity of 42.25.
  • Our Pulse grade checklist scores it F (23/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
  • Annualised volatility over the past year is 25.31% with a maximum drawdown of -26.59% and a beta of 0.67 against NIFTY 50.
  • Recent coverage: Biocon share price rises nearly 6% despite 52% dip in Q2 profit
  • Recent coverage: Biocon Q2 profit halves to ₹41 crore as delayed shipments weigh on margins

Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma

Last traded values from 20 Nov 2026. Closed — weekend.

Biocon

₹364.8

▲ 1.15 (+0.32%)

Price & volume

BIOCON price chart, 1Y range. 252 points from 2025-11-24 to 2026-11-20. Opens at 395.25, closes at 364.8, ranging between 323.5 and 440.7.350400Nov-25Jan-26Mar-26May-26Jun-26Aug-26Sep-26Nov-26volume

Hover for exact price & volume · green/red volume bars show up vs down days

Neutral momentum · 3/5
✓ Above 50-day avg✕ Above 200-day avgRSI 54.6 · healthyMACD positiveBollinger %B 67ADX 21 · weak trend

1M

+7.29%

3M

-11.56%

6M

-15.69%

1Y

-7.68%

Where it sits in its 52-week range

35%
₹323.5₹440.7

Below 52-week high

17.2%

12.8% above the low

Momentum read

Neutral

3/5 checks passed

52-wk high

₹440.7

52-wk low

₹323.5

Market cap

—

P/E (trailing)

—

Dividend yield

—

ROE

—

Profit margin

—

Revenue growth

—

Price / Book

—

Debt / Equity

—

EPS (TTM)

—

Book value

—

Beta

0.67

Pulse grade: F, 19 out of 100

Momentum

C
  • ✓Trading above 50-day average
  • ✕Trading above 200-day average
  • ✓RSI in healthy 45-70 zone
  • ✕Positive 3-month return

Growth

F
  • ✕Revenue growth above 12%
  • ✕Revenue growing above 5%
  • ✕Quarterly profits trending up

Profitability

F
  • ✕Return on equity above 18%
  • ✕Return on equity above 12%
  • ✕Profit margin above 12%

Safety

F
  • ✕Debt below 50
  • ✕Debt not extreme for the sector
  • ✓Less volatile than the market (beta < 1.2)
  • ✕Pays a dividend

Quarterly revenue vs net profit

Revenue Net profit₹ crore, by quarter

Sep 2026: revenue ₹4,345 crore · net profit ₹41 crore · margin 0.9%

4,4840Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026

Business quality

Intrinsic value

Building the model…

Analyst coverage

Who owns this company

Events, dividends & splits

Market position

Pharma & Healthcare sector

PeerPrice ₹Day changeFrom 52-wk high
SUNPHARMA1,887.5-0.66%-5.68%
DRREDDY1,394.5-0.26%-0.46%
CIPLA1,413.9-0.32%-7.67%
DIVISLAB11,138.5-0.35%-3.69%
APOLLOHOSP9,254+5.91%+2.04%
LUPIN2,006.6+0.39%-20.21%

BIOCON headlines

No BIOCON stories right now.

BIOCON filings & announcements

Reading the exchange…

BIOCON, historical timeline

The timeline will be ready shortly

The rest of the page is unaffected.

Risk & return, last 12 months

Volatility (ann.)

25.31%

Sharpe ratio

-0.44

Sortino ratio

-0.63

Max drawdown

-26.59%

Daily VaR (95%)

-2.47%

CAGR (1Y)

-7.73%

Return skew

0.31

Sharpe/Sortino use a 7% risk-free rate. VaR-95 = the daily loss exceeded only 5% of days last year.

Risk profile over time

Quant tearsheet

Monthly returns, how deep the falls ran, and how tightly it tracks NIFTY.